文献速递泌尿男性生殖肿瘤

新辅助戈沙妥珠单抗联合帕博利珠单抗序贯辅助帕博利珠单抗治疗肌层浸润性膀胱癌(SURE-02):单臂2期研究

Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
PubMed 文献 · Lancet Oncol · 2026-02-27

SURE-02是一项在意大利米兰IRCCS San Raffaele医院开展的单臂2期研究,纳入49例不适合或拒绝顺铂新辅助化疗的肌层浸润性膀胱癌患者。患者接受4周期新辅助戈沙妥珠单抗联合帕博利珠单抗,随后行根治性膀胱切除术或再行经尿道膀胱肿瘤电切术(re-TURBT),术后接受13周期帕博利珠单抗辅助治疗。中位随访14个月,临床完全缓解率为39%(95% CI 25-54),所有缓解者均未发生转移,约40%患者实现保留膀胱。

要点

  • 不适合或拒绝顺铂化疗的MIBC患者中,新辅助戈沙妥珠单抗联合帕博利珠单抗的临床完全缓解率为39%。
  • 所有临床完全缓解者均无转移,仅2例出现膀胱内复发,约40%患者实现保留膀胱。
  • 3级治疗相关不良事件发生率为16%,无4级及以上不良事件及治疗相关死亡。

核心结论

  • 围手术期戈沙妥珠单抗联合帕博利珠单抗在肌层浸润性膀胱癌中显示出有前景的临床完全缓解率,未发生4级及以上不良事件,约40%患者实现保留膀胱并维持缓解。

研究设计与样本

  • SURE-02为单臂2期研究,在意大利米兰IRCCS San Raffaele医院开展,纳入49例新诊断的cT2-T3bN0M0期肌层浸润性膀胱癌患者。
  • 主要终点为未行根治性膀胱切除术患者的临床完全缓解率,定义为影像学阴性且re-TURBT无存活肿瘤。

主要发现

  • 中位随访14个月(IQR 8-18),19例(39% [95% CI 25-54])患者达到临床完全缓解,均接受了re-TURBT。
  • 所有临床完全缓解者均无转移,2例出现膀胱内复发。
  • 3级治疗相关不良事件发生于8例(16%),最常见为腹泻(4例 [8%]);3例(6%)发生严重治疗相关不良事件,分别为大疱性类天疱疮2例和结肠炎1例。
  • 无治疗相关死亡。

关键数值与推荐

  • 临床完全缓解率定义为影像学阴性且re-TURBT无存活肿瘤,在未行根治性膀胱切除术的患者中评估。
  • 疗效在至少接受一剂研究治疗且有基线评估的患者(意向治疗人群)中评估。

临床怎么用

  • 对于不适合或拒绝顺铂新辅助化疗的肌层浸润性膀胱癌患者,该围手术期方案可能提供保留膀胱的选择。
  • 临床完全缓解者经re-TURBT确认后可暂不行根治性膀胱切除术,但需密切监测膀胱内复发。

局限性

  • 单臂设计,无对照,样本量较小(49例)。
  • 随访时间较短(中位14个月),长期肿瘤学结局尚不明确。
  • 研究仅在单一中心开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard-of-care treatment for muscle-invasive bladder cancer is radical cystectomy with neoadjuvant chemotherapy; however, approximately 50% of patients are ineligible for or refuse neoadjuvant chemotherapy. Neoadjuvant pembrolizumab and sacituzumab govitecan have shown activity as monotherapy in muscle-invasive bladder cancer. We aimed to evaluate the clinical activity of neoadjuvant sacituzumab govitecan plus pembrolizumab and adjuvant pembrolizumab, within a bladder-sparing approach. METHODS: SURE-02 is a single-arm, phase 2 study, conducted at IRCCS San Raffaele Hospital in Milan, Italy. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status 0-1, were newly diagnosed with histologically confirmed muscle-invasive bladder cancer (stage cT2-T3bN0M0), were deemed ineligible for or declined cisplatin-based neoadjuvant chemotherapy, and were scheduled for radical cystectomy. Patients received four cycles of intravenous pembrolizumab 200 mg on day 1 and intravenous sacituzumab govitecan 7·5 mg/kg on day 1 and day 8, every 3 weeks, followed by radical cystectomy or redo-transurethral resection of the bladder tumour (re-TURBT; after multidisciplinary tumour board discussion in patients who refused to undergo radical cystectomy) and 13 cycles of postsurgical pembrolizumab 200 mg, every 3 weeks. The primary endpoint was the clinical complete response rate, defined as negative imaging and no viable tumour at re-TURBT in patients not undergoing radical cystectomy. Efficacy was assessed in all patients who received at least one dose of study treatment and had a baseline evaluation (intention-to-treat population). This study is registered with ClinicalTrials.gov, NCT05535218, and is active but not recruiting. FINDINGS: Between Oct 2, 2023, and Feb 26, 2025, 63 patients were screened, 49 patients (median age 66 years [IQR 61-71]; eight [16%] female and 41 [84%] male; 48 [98%] White and one [2%] Black) were enrolled, treated, and evaluated for safety and efficacy. 33 (67%) had a cT2 stage, 21 (43%) had a centrally confirmed variant histology. After a median follow-up of 14 months (IQR 8-18), 19 (39% [95% CI 25-54]) patients had a clinical complete response; all of whom underwent a re-TURBT. All patients with clinical complete response were metastasis-free; two patients developed an intravesical relapse. Grade 3 treatment-related adverse-events occurred in eight patients (16%), the most common being diarrhoea (in four [8%]). There were no treatment-related deaths. Serious treatment-related adverse events were reported in three patients (6%); bullous pemphigoid in two and colitis in one patient respectively. INTERPRETATION: Perioperative sacituzumab govitecan plus pembrolizumab revealed a promising clinical complete response rate, without the occurrence of grade 4 or higher adverse events, allowing a bladder preservation with sustained remission in approximately 40% of patients. FUNDING: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA and Gilead Sciences.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Necchi A, Maiorano BA, de Jong JJ, et al. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol. 2026. PMID: 41771275. doi:10.1016/S1470-2045(26)00050-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。